119 related articles for article (PubMed ID: 1910485)
1. Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
Prell GD; Khandelwal JK; Burns RS; Blandina P; Morrishow AM; Green JP
J Neural Transm Park Dis Dement Sect; 1991; 3(2):109-25. PubMed ID: 1910485
[TBL] [Abstract][Full Text] [Related]
2. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
[TBL] [Abstract][Full Text] [Related]
3. Increase of striatal dopamine turnover by stress in MPTP-treated mice.
Urakami K; Masaki N; Shimoda K; Nishikawa S; Takahashi K
Clin Neuropharmacol; 1988 Aug; 11(4):360-8. PubMed ID: 3264755
[TBL] [Abstract][Full Text] [Related]
4. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Muthian G; Mackey V; King J; Charlton CG
Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
[TBL] [Abstract][Full Text] [Related]
5. Cognitive changes in mice following moderate MPTP exposure.
Tanila H; Björklund M; Riekkinen P
Brain Res Bull; 1998 Apr; 45(6):577-82. PubMed ID: 9566501
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Boireau A; Bordier F; Dubédat P; Pény C; Impérato A
Neurosci Lett; 1997 Oct; 234(2-3):123-6. PubMed ID: 9364513
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) effects on enkephalinergic neurons in various regions of mouse brain.
Mitsuo K; Cosi C; Harvey-White JD; Schwartz JP
Neurochem Int; 1993 Feb; 22(2):175-82. PubMed ID: 8439770
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Plangár I; Zádori D; Szalárdy L; Vécsei L; Klivényi P
Ideggyogy Sz; 2013 Nov; 66(11-12):407-14. PubMed ID: 24555241
[TBL] [Abstract][Full Text] [Related]
10. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice.
Marien M; Briley M; Colpaert F
Eur J Pharmacol; 1993 Jun; 236(3):487-9. PubMed ID: 7689466
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Date I; Felten DL; Felten SY
Brain Res; 1990 Jun; 519(1-2):266-76. PubMed ID: 1975765
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
13. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
14. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.
Tabatabaei A; Perry TL; Hansen S; Krieger C
Neurosci Lett; 1992 Jul; 141(2):192-4. PubMed ID: 1436633
[TBL] [Abstract][Full Text] [Related]
15. Depletion of cardiac norepinephrine but not brain catecholamines by MPTP-N-oxide in mice.
Hemrick-Luecke SK; Robertson DW; Fuller RW
Life Sci; 1990; 47(9):815-9. PubMed ID: 2215082
[TBL] [Abstract][Full Text] [Related]
16. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
17. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Feng G; Zhang Z; Bao Q; Zhang Z; Zhou L; Jiang J; Li S
Biol Pharm Bull; 2014; 37(8):1301-7. PubMed ID: 24871044
[TBL] [Abstract][Full Text] [Related]
19. Increased striatal dopamine turnover following acute administration of rotenone to mice.
Thiffault C; Langston JW; Di Monte DA
Brain Res; 2000 Dec; 885(2):283-8. PubMed ID: 11102582
[TBL] [Abstract][Full Text] [Related]
20. Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine , an analog of MPTP, on mouse heart norepinephrine and brain catecholamines.
Hemrick-Luecke SK; Mitch CH; Quimby SJ; Fuller RW
Neurochem Int; 1993 Nov; 23(5):467-70. PubMed ID: 8251928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
